Ibrutinib

RED:

NICE TA429: for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (decision date - Feb 2017)
NICE TA491: Ibrutinib for treating Waldenstrom's macroglobulinaemia (decision date - Dec 2017)
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma. (Decision date - February 2018)
NICE TA891 - Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia. (Decision date – June 2023)

DO NOT PRESCRIBE (DNP):

NICE TA437: Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (decision date - April 2017)
NICE TA452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) (decision date - Aug 2017)
NICE TA608: Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia. (Terminated appraisal) (Decision date - December 2019)
NICE TA702 - Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) (Decision date - July 2021)
NICE TA703 - Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) (Decision date - July 2021)
NICE TA795 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia. NHSE commissioned. (Decision date - July 2022)

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)